Ernexa Therapeutics appoints Robert J. Spiegel to board
Ernexa Therapeutics appointed Robert J. Spiegel, M.D., FACP, to its Board of Directors as it advances ERNA-101 toward clinical development.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
Ernexa Therapeutics appointed Robert J. Spiegel, M.D., FACP, to its Board of Directors as it advances ERNA-101 toward clinical development.
Ernexa Therapeutics appointed biopharmaceutical executive Robert J. Spiegel, M.D., FACP, to its Board of Directors. The company said the appointment strengthens the board as it advances ERNA-101 toward clinical development.
ERNA - Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Ernexa appointed Robert J. Spiegel, M.D. to its board of directors, effective September 14, 2026.